- Pre-malignant Lesions
- Early Invasive Stage
- Advanced Invasive Stage
Cervical Cancer Treatment Market is expected to be valued at US$ 6,490.9 million in 2022 and is poised to grow at a significant CAGR of 5.2% from 2023-2029. Increased incidence of cervical cancer, constructive public policies and the emergence of targeted therapies act as drivers to the global market. There are few restrain which hung the market such as lack of awareness other factors, high cost of treatment, and adverse effects. Rising R & D expenditure in oncologic diseases provide multiple opportunities towards the global cervical cancer treatment market. This report studies global cervical cancer treatment market dynamics elaborately to identify the current trends & drivers, future opportunities and possible challenges to the key stakeholders operating in the market. In addition, global cervical cancer treatment market report includes human demographics; regulatory scenario, and competition analysis with vividly illustrated the competition dashboard to assess the market competition. Moreover, PBI analyzed global cervical cancer treatment market to better equip clients with possible investment opportunities across the regions (regional Investment Hot-Spots) and market unmet needs (Cancer Type Opportunities). Key stakeholders of the global market report include suppliers, manufacturers, marketers, policy makers, and service providers engaged in global cervical cancer treatment market
Cervical Cancer Treatment Market Key Developments:
- In March 2018, The American Cancer Society awarded US$ 9,3 million in funding for cervical cancer for 22 distinct types of grants, this sum can be given to a particular form of cancer for a single or group of researchers.
Cervical Cancer Treatment Market Summary
Study Period
2024-2030
Base Year
2023
CAGR
5.2%
Largest Market
North America
Fastest Growing Market
Europe
Cervical Cancer Treatment Market
Increase in the prevalence of cervical cancer around the world is mainly drives the global cervical cancer treatment market. Moreover, advancements in the cervical cancer treatment, early stage disease diagnosis, promising pipeline products, and government initiations for increase the cervical cancer treatment awareness are anticipated to fuel global cervical cancer treatment market over the forecast years. However, high cost for cervical cancer treatment, stringent regulatory guidelines for product approval, entry of generics into the market and adverse effects associated with radiation therapy are expected to restrain the growth of global cervical cancer treatment market.
Cervical Cancer Treatment Market Regional Analysis
North America dominates the market
North America cervical cancer treatment market is anticipated to expand at healthy growth rate due to increase in the prevalence of cervical cancer (according to Centers for Disease Control and Prevention 2014, approximately 12,578 women are diagnosed with cervical cancer), technological advancements for early stage disease diagnosis, and increase in R&D expenditure for the innovation of newer products are anticipated to fuel the market. Europe cervical cancer treatment market driven by increase in the prevalence of cervical cancer in Europe (according to WHO Europe, approximately 28,000 women die from cervical cancer every year), expansion of business by market players, and adoption of newer technologies for surgical cancer treatment are expected to boost the market.
Latin America
Europe
Asia Pacific
Middle East
North America
Key Features of the Reports
- The report provides granular level information about the market size, regional market share, historic market (2018-2022) and forecast (2023-2029)
- The report covers in-detail insights about the competitors overview, company share analysis, key market developments, and their key strategies
- The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market
- The report tracks recent innovations, key developments and startups details that are actively working in the market
- The report provides plethora of information about market entry strategies, regulatory framework and reimbursement scenario
- The report analyses the impact of socio-political environment through PESTLE Analysis and competition through Porters Five Force Analysis in addition to recent technology advancements and innovations in the market
Cervical Cancer Treatment Market Segmentation
By Disease Indication
By Treatment Type
- Simple Hysterectomy
- Radical Trachelectomy
- Cryotherapy
- Laser Surgery
- Cold Knife Cone Biopsy
- Cone Biopsy
- LEEP (Loop Electrosurgical Exclusion Procedure)
- Chemotherapy
- Hormone Therapy
- Radiation Therapy
- Targeted Therapy
- Others
By End-User
- Hospitals
- Ambulatory Surgical Centers
- Pharmacies
By Geography
- North America
- Latin America
- Europe
- Asia Pacific
- Middle East and Africa
Frequently Asked Questions
The key segments covered in the Cervical Cancer Treatment Market are technology, components, application, and end-users.
The Cervical Cancer Treatment Market has been classified into North America, Asia Pacific, Europe, Latin America, Middle East and Africa, and the rest of MEA.
The Cervical Cancer Treatment Market key players Pfizer Inc., GlaxoSmithKline, Bristol-Myers Squibb Company, ALLERGAN, Actavis Pharma Company, Eli Lilly and Company, Alnylam Pharmaceuticals, Hetero, Biocon, Novartis
| 1. Executive Summary |
| 2. Global Cervical Cancer Treatment Market Introduction |
| 2.1. Global Cervical Cancer Treatment Market - Taxonomy |
| 2.2. Global Cervical Cancer Treatment Market -Definitions |
| 2.2.1. Cancer Type |
| 2.2.2. Treatment |
| 2.2.3. End User |
| 3. Global Cervical Cancer Treatment Market Dynamics |
| 3.1. Drivers |
| 3.2. Restraints |
| 3.3. Opportunities/Unmet Needs of the Market |
| 3.4. Trends |
| 3.5. Global Cervical Cancer Treatment Market Dynamic Factors - Impact Analysis |
| 3.6. Global Cervical Cancer Treatment Market - Competition Landscape |
| 4. Global Cervical Cancer Treatment Market Analysis, 2018-2022 and Forecast, 2023-2029 |
| 4.1. Market Analysis, 2018-2022 and Forecast, 2023-2029 (Revenue, USD Mn) |
| 4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) |
| 4.3. Market Opportunity Analysis |
| 5. Global Cervical Cancer Treatment Market, By Cancer Type, 2018-2022 and Forecast, 2023-2029 (Revenue, USD Mn) |
| 5.1. Squamous Cell Carcinomas |
| 5.1.1. Market Analysis, 2018-2022 and Forecast, 2023-2029 (Revenue, USD Mn) |
| 5.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.1.3. Market Opportunity Analysis |
| 5.2. Adenocarcinomas |
| 5.2.1. Market Analysis, 2018-2022 and Forecast, 2023-2029 (Revenue, USD Mn) |
| 5.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.2.3. Market Opportunity Analysis |
| 5.3. Adenosquamous Carcinomas |
| 5.3.1. Market Analysis, 2018-2022 and Forecast, 2023-2029 (Revenue, USD Mn) |
| 5.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.3.3. Market Opportunity Analysis |
| 5.4. Others |
| 5.4.1. Market Analysis, 2018-2022 and Forecast, 2023-2029 (Revenue, USD Mn) |
| 5.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.4.3. Market Opportunity Analysis |
| 6. Global Cervical Cancer Treatment Market Forecast, By Treatment, 2018-2022 and Forecast, 2023-2029 (Revenue, USD Mn) |
| 6.1. Surgery |
| 6.1.1. Market Analysis, 2018-2022 and Forecast, 2023-2029 (Revenue, USD Mn) |
| 6.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.1.3. Market Opportunity Analysis |
| 6.2. Radiation Therapy |
| 6.2.1. Market Analysis, 2018-2022 and Forecast, 2023-2029 (Revenue, USD Mn) |
| 6.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.2.3. Market Opportunity Analysis |
| 6.3. Chemotherapy |
| 6.3.1. Market Analysis, 2018-2022 and Forecast, 2023-2029 (Revenue, USD Mn) |
| 6.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.3.3. Market Opportunity Analysis |
| 6.4. Targeted Therapy |
| 6.4.1. Market Analysis, 2018-2022 and Forecast, 2023-2029 (Revenue, USD Mn) |
| 6.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.4.3. Market Opportunity Analysis |
| 6.5. Hormone Therapy |
| 6.5.1. Market Analysis, 2018-2022 and Forecast, 2023-2029 (Revenue, USD Mn) |
| 6.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.5.3. Market Opportunity Analysis |
| 6.6. Others |
| 6.6.1. Market Analysis, 2018-2022 and Forecast, 2023-2029 (Revenue, USD Mn) |
| 6.6.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.6.3. Market Opportunity Analysis |
| 7. Global Cervical Cancer Treatment Market Forecast, By End User, 2018-2022 and Forecast, 2023-2029 |
| 7.1. Cancer Care Centers |
| 7.1.1. Market Analysis, 2018-2022 and Forecast, 2023-2029 (Revenue, USD Mn) |
| 7.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.1.3. Market Opportunity Analysis |
| 7.2. Diagnostic Centers |
| 7.2.1. Market Analysis, 2018-2022 and Forecast, 2023-2029 (Revenue, USD Mn) |
| 7.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.2.3. Market Opportunity Analysis |
| 7.3. Pharmacies |
| 7.3.1. Market Analysis, 2018-2022 and Forecast, 2023-2029 (Revenue, USD Mn) |
| 7.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.3.3. Market Opportunity Analysis |
| 7.4. Others |
| 7.4.1. Market Analysis, 2018-2022 and Forecast, 2023-2029 (Revenue, USD Mn) |
| 7.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.4.3. Market Opportunity Analysis |
| 8. Global Cervical Cancer Treatment Market Forecast, By Region, 2018-2022 and Forecast, 2023-2029 (Revenue, USD Mn) |
| 8.1. North America |
| 8.1.1. Market Analysis, 2018-2022 and Forecast, 2023-2029 (Revenue, USD Mn) |
| 8.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 8.1.3. Market Opportunity Analysis |
| 8.2. Europe |
| 8.2.1. Market Analysis, 2018-2022 and Forecast, 2023-2029 (Revenue, USD Mn) |
| 8.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 8.2.3. Market Opportunity Analysis |
| 8.3. Asia-Pacific |
| 8.3.1. Market Analysis, 2018-2022 and Forecast, 2023-2029 (Revenue, USD Mn) |
| 8.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 8.3.3. Market Opportunity Analysis |
| 8.4. Latin America |
| 8.4.1. Market Analysis, 2018-2022 and Forecast, 2023-2029 (Revenue, USD Mn) |
| 8.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 8.4.3. Market Opportunity Analysis |
| 8.5. Middle East and Africa |
| 8.5.1. Market Analysis, 2018-2022 and Forecast, 2023-2029 (Revenue, USD Mn) |
| 8.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 8.5.3. Market Opportunity Analysis |
| 8.6. Global Cervical Cancer Treatment Market - Opportunity Analysis Index, By Cancer Type, Treatment, End User and Region, 2023-2029 |
| 9. North America Cervical Cancer Treatment Market Analysis, 2018-2022 and Forecast, 2023-2029 (Revenue, USD Mn) |
| 9.1. Cancer Type Analysis 2018-2022 and Forecast 2023-2029 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%) |
| 9.1.1. Squamous Cell Carcinomas |
| 9.1.2. Adenocarcinomas |
| 9.1.3. Adenosquamous Carcinomas |
| 9.1.4. Others |
| 9.2. Treatment Analysis 2018-2022 and Forecast 2023-2029 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%) |
| 9.2.1. Surgery |
| 9.2.2. Radiation Therapy |
| 9.2.3. Chemotherapy |
| 9.2.4. Targeted Therapy |
| 9.2.5. Hormone Therapy |
| 9.2.6. Others |
| 9.3. End User Analysis 2018-2022 and Forecast 2023-2029 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%) |
| 9.3.1. Cancer Care Centers |
| 9.3.2. Diagnostic Centers |
| 9.3.3. Pharmacies |
| 9.3.4. Others |
| 9.4. Country Analysis 2018-2022 and Forecast 2023-2029 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%) |
| 9.4.1. USA |
| 9.4.2. Canada |
| 9.5. North America Cervical Cancer Treatment Market - Opportunity Analysis Index, By Cancer Type, Treatment, End User and Country, 2023-2029 |
| 9.6. North America Cervical Cancer Treatment Market Dynamics - Trends |
| 10. Europe Cervical Cancer Treatment Market Analysis, 2018-2022 and Forecast, 2023-2029 (Revenue, USD Mn) |
| 10.1. Cancer Type Analysis 2018-2022 and Forecast 2023-2029 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%) |
| 10.1.1. Squamous Cell Carcinomas |
| 10.1.2. Adenocarcinomas |
| 10.1.3. Adenosquamous Carcinomas |
| 10.1.4. Others |
| 10.2. Treatment Analysis 2018-2022 and Forecast 2023-2029 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%) |
| 10.2.1. Surgery |
| 10.2.2. Radiation Therapy |
| 10.2.3. Chemotherapy |
| 10.2.4. Targeted Therapy |
| 10.2.5. Hormone Therapy |
| 10.2.6. Others |
| 10.3. End User Analysis 2018-2022 and Forecast 2023-2029 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%) |
| 10.3.1. Cancer Care Centers |
| 10.3.2. Diagnostic Centers |
| 10.3.3. Pharmacies |
| 10.3.4. Others |
| 10.4. Country Analysis 2018-2022 and Forecast 2023-2029 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%) |
| 10.4.1. Germany |
| 10.4.2. UK |
| 10.4.3. France |
| 10.4.4. Spain |
| 10.4.5. Italy |
| 10.4.6. Russia |
| 10.4.7. Poland |
| 10.4.8. Rest of Europe |
| 10.5. Europe Cervical Cancer Treatment Market - Opportunity Analysis Index, By Cancer Type, Treatment, End User and Country, 2023-2029 |
| 10.6. Europe Cervical Cancer Treatment Market Dynamics - Trends |
| 11. Asia-Pacific Cervical Cancer Treatment Market Analysis, 2018-2022 and Forecast, 2023-2029 (Revenue, USD Mn) |
| 11.1. Cancer Type Analysis 2018-2022 and Forecast 2023-2029 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%) |
| 11.1.1. Squamous Cell Carcinomas |
| 11.1.2. Adenocarcinomas |
| 11.1.3. Adenosquamous Carcinomas |
| 11.1.4. Others |
| 11.2. Treatment Analysis 2018-2022 and Forecast 2023-2029 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%) |
| 11.2.1. Surgery |
| 11.2.2. Radiation Therapy |
| 11.2.3. Chemotherapy |
| 11.2.4. Targeted Therapy |
| 11.2.5. Hormone Therapy |
| 11.2.6. Others |
| 11.3. End User Analysis 2018-2022 and Forecast 2023-2029 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%) |
| 11.3.1. Cancer Care Centers |
| 11.3.2. Diagnostic Centers |
| 11.3.3. Pharmacies |
| 11.3.4. Others |
| 11.4. Country Analysis 2018-2022 and Forecast 2023-2029 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%) |
| 11.4.1. Japan |
| 11.4.2. China |
| 11.4.3. India |
| 11.4.4. ASEAN |
| 11.4.5. Australia & New Zealand |
| 11.4.6. Rest of Asia-Pacific |
| 11.5. Asia-Pacific Cervical Cancer Treatment Market - Opportunity Analysis Index, By Cancer Type, Treatment, End User and Country, 2023-2029 |
| 11.6. Asia-Pacific Cervical Cancer Treatment Market Dynamics - Trends |
| 12. Latin America Cervical Cancer Treatment Market Analysis, 2018-2022 and Forecast, 2023-2029 (Revenue, USD Mn) |
| 12.1. Cancer Type Analysis 2018-2022 and Forecast 2023-2029 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%) |
| 12.1.1. Squamous Cell Carcinomas |
| 12.1.2. Adenocarcinomas |
| 12.1.3. Adenosquamous Carcinomas |
| 12.1.4. Others |
| 12.2. Treatment Analysis 2018-2022 and Forecast 2023-2029 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%) |
| 12.2.1. Surgery |
| 12.2.2. Radiation Therapy |
| 12.2.3. Chemotherapy |
| 12.2.4. Targeted Therapy |
| 12.2.5. Hormone Therapy |
| 12.2.6. Others |
| 12.3. End User Analysis 2018-2022 and Forecast 2023-2029 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%) |
| 12.3.1. Cancer Care Centers |
| 12.3.2. Diagnostic Centers |
| 12.3.3. Pharmacies |
| 12.3.4. Others |
| 12.4. Country Analysis 2018-2022 and Forecast 2023-2029 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%) |
| 12.4.1. Brazil |
| 12.4.2. Mexico |
| 12.4.3. Argentina |
| 12.4.4. Rest of Latin America |
| 12.5. Latin America Cervical Cancer Treatment Market - Opportunity Analysis Index, By Cancer Type, Treatment, End User and Country, 2023-2029 |
| 12.6. Latin America Cervical Cancer Treatment Market Dynamics - Trends |
| 13. Middle East and Africa Cervical Cancer Treatment Market Analysis, 2018-2022 and Forecast, 2023-2029 (Revenue, USD Mn) |
| 13.1. Cancer Type Analysis 2018-2022 and Forecast 2023-2029 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%) |
| 13.1.1. Squamous Cell Carcinomas |
| 13.1.2. Adenocarcinomas |
| 13.1.3. Adenosquamous Carcinomas |
| 13.1.4. Others |
| 13.2. Treatment Analysis 2018-2022 and Forecast 2023-2029 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%) |
| 13.2.1. Surgery |
| 13.2.2. Radiation Therapy |
| 13.2.3. Chemotherapy |
| 13.2.4. Targeted Therapy |
| 13.2.5. Hormone Therapy |
| 13.2.6. Others |
| 13.3. End User Analysis 2018-2022 and Forecast 2023-2029 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%) |
| 13.3.1. Cancer Care Centers |
| 13.3.2. Diagnostic Centers |
| 13.3.3. Pharmacies |
| 13.3.4. Others |
| 13.4. Country Analysis 2018-2022 and Forecast 2023-2029 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%) |
| 13.4.1. Gulf Cooperation Council (GCC) Countries |
| 13.4.2. Israel |
| 13.4.3. South Africa |
| 13.4.4. Rest of MEA |
| 13.5. MEA Cervical Cancer Treatment Market - Opportunity Analysis Index, By Cancer Type, Treatment, End User and Country, 2023-2029 |
| 13.6. MEA Cervical Cancer Treatment Market Dynamics - Trends |
| 14. Competition Landscape |
| 14.1. Strategic Dashboard of Top Market Players |
| 14.2. Company Profiles (Introduction, Financial Analysis, Cancer Type & Service Offerings, Key Developments, Strategies, and SWOT Analysis) |
| 14.2.1. Pfizer Inc. |
| 14.2.2. GlaxoSmithKline |
| 14.2.3. Bristol-Myers Squibb Company |
| 14.2.4. ALLERGAN |
| 14.2.5. Actavis Pharma Company |
| 14.2.6. Eli Lilly and Company |
| 14.2.7. Alnylam Pharmaceuticals |
| 14.2.8. Hetero |
| 14.2.9. Biocon |
| 14.2.10. Novartis |
| 15. Research Methodology |
| 16. Key Assumptions and Acronyms |
- Pfizer Inc.
- GlaxoSmithKline
- Bristol-Myers Squibb Company
- ALLERGAN
- Actavis Pharma Company
- Eli Lilly and Company
- Alnylam Pharmaceuticals
- Hetero
- Biocon
- Novartis